Systems biology and OMIC data integration to understand gastrointestinal cancers

Iasmin Moreira Costa Bispo, Henry Paul Granger, Palloma Porto Almeida, Patricia Belini Nishiyama, Leandro Martins de Freitas

Abstract
Gastrointestinal (GI) cancers are a set of diverse diseases affecting many parts/organisms. The five most frequent GI cancer types are esophageal, gastric cancer (GC), liver cancer, pancreatic cancer, and colorectal cancer (CRC); together, they give rise to 5 million new cases and cause the death of 3.5 million people annually. We provide information about molecular changes crucial to tumorigenesis and the behavior and prognosis. During the formation of cancer cells, the genomic changes are microsatellite instability with multiple chromosomal arrangements in GC and CRC. The genomically stable subtype is observed in GC and pancreatic cancer. Besides these genomic subtypes, CRC has epigenetic modification (hypermethylation) associated with a poor prognosis. The pathway information highlights the functions shared by GI cancers such as apoptosis; focal adhesion; and the p21-activated kinase, phosphoinositide 3-kinase/Akt, transforming growth factor beta, and Toll-like receptor signaling pathways. These pathways show survival, cell proliferation, and cell motility. In addition, the immune response and inflammation are also essential elements in the shared functions. We also retrieved information on protein-protein interaction from the STRING database, and found that proteins Akt1, catenin beta 1 (CTNNB1), E1A binding protein P300, tumor protein p53 (TP53), and TP53 binding protein 1 (TP53BP1) are central nodes in the network. The protein expression of these genes is associated with overall survival in some GI cancers. The low TP53BP1 expression in CRC, high EP300 expression in esophageal cancer, and increased expression of Akt1/TP53 or low CTNNB1 expression in GC are associated with a poor prognosis. The Kaplan Meier plotter database also confirmed the association between expression of the five central genes and GC survival rates. In conclusion,
GI cancers are very diverse at the molecular level. However, the shared mutations and protein pathways might be used to understand better and reveal diagnostic/prognostic or drug targets.

**Key Words:** Gastrointestinal cancers; Genome; Cellular pathways; Protein-protein interaction; Prognosis; OMIC data

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

---

**Core Tip:** We highlight the genomic mutations and cellular pathways in gastrointestinal (GI) cancers. These are responsible for the cell’s behavior, allowing unlimited cell replication and invasion of other tissues. Using the STRING database, we found that Akt1, catenin beta 1, E1A binding protein p300, tumor protein p53 (TP53), and TP53 binding protein 1 are central nodes in the GI cancer protein network. Their expression is associated with poor survival in some GI cancers, which was confirmed by the Kaplan Meier plotter database. This information points to crucial and shared aspects of the most frequent GI cancers.

---

**Citation:** Bispo IMC, Granger HP, Almeida PP, Nishiyama PB, de Freitas LM. Systems biology and OMIC data integration to understand gastrointestinal cancers. **World J Clin Oncol** 2022; 13(10): 762-778

**URL:** https://www.wjgnet.com/2218-4333/full/v13/i10/762.htm

**DOI:** https://dx.doi.org/10.5306/wjco.v13.i10.762

---

**INTRODUCTION**

In 2020, the number of cancer cases in the digestive system was 5 million and 3.5 million deaths worldwide[1,2]; the physiologic system with the highest number of cases and among the highest percentage of deaths[3] (Table 1). The cancer types in this system can be classified as organ origin and cell type. The most frequent are esophageal cancer (EC), gastric cancer (GC), liver cancer, pancreatic cancer, and colorectal cancer (CRC)[2,3]. GC, liver cancer, and CRC are among the most common causes of cancer deaths annually[2]. Gastrointestinal (GI) cancers also have specific molecular changes in genetic/genome, epigenetics, gene expression, and cellular pathways contributing to tumor behavior. This information might be helpful in diagnosis, prognosis, and new drug development.

**EC**

EC has two subtypes: esophageal squamous cell cancer (ESCC) and esophageal adenocarcinoma (EAC) [4]. The incidence of ESCC increases globally and predominantly in Eastern Asia and Eastern/Southern Africa[4-7]. However, the ESCC decreases while EAC increases in the United States and a few European countries[5]. The ESCC and EAC incidence differences are geographically observed in sex and ethnic patterns[4,5].

There is also a well-established genetic factor associated with sex, and although it is still not well understood, it is known that the ratio between men to women is 2.5-4.4:1[4,6]. Studies indicate a protective effect of female sex hormones, including a lower risk of cancer for women previously breastfed. Nevertheless, environmental factors also influence this prevalence as, for example, men tend to abuse alcohol and tobacco, which are primary risk factors for the manifestation of EC[4,8].

The risk factors for ESCC are smoking, a low vegetables/fruit diet, and alcohol consumption[9], whereas for EAC, the risk factors are obesity and gastroesophageal reflux disease[9,10]. When alcohol and tobacco are used together, there is an increased risk. This combination is believed to be responsible for 70%-90% of cases, mainly because they cause chronic irritation and inflammation of the esophageal mucosa. In the case of obesity, the greater the abdominal circumference, the greater the intra-abdominal pressure increases the probability of developing gastroesophageal reflux[4,6,11-14].

Early diagnosis is fundamental to improving prognosis. However, dysplasia usually is asymptomatic [4,11,12,15] and manifests at an average age of 67 years, when there is a high incidence of metastasis, mainly in lymph nodes, liver, lungs, and bones[11,12]. These features make the EC an aggressive malignancy with a 15%-23% 5-year survival rate[9,10].

**GC**

GC has the fourth highest incidence and mortality worldwide[1,2]. The primary risk factors for GC are genetics, diet (high amount of salt and low consumption of fruits and vegetables), *Helicobacter pylori* or Epstein–Barr virus infection, smoking, alcohol intake, and sedentary life[16-19]. The principal risk factor for GC is *H. pylori* infection, accounting for 80% of the cases. Although the incidence of *H. pylori* infection is decreasing, GC deaths are still high. While the primary risk factor is *H. pylori* infection, many...
genes are associated with GC[16,18,20], and some genetic variations that can interact with *H. pylori* increase the GC risk[21,22]. The incidence of GC is higher in males (1.32-2.2) and in Eastern/Central Asia and Latin America[16,18].

Obesity can induce inflammation of the stomach lining through tumor necrosis factor (TNF), interleukin 6 (IL-6), and C-C motif chemokine ligand 2. By contrast, a diet rich in fruits and vegetables has proven to be an ally in cancer prevention because it contains numerous antioxidants that prevent metabolic damage, especially vitamin C[18].

A relevant factor in the decline of GC has been the successful prevention and treatment of infections by *H. pylori*[18]. According to the International Agency for Research on Cancer, this is a carcinogen from group 1, meaning there is sufficient evidence of human carcinogenicity[23,24]. *H. pylori* infection affects more than half of the world’s population, and its eradication may considerably decrease the chances of stomach cancer. However, it would increase the chances of esophageal adenocarcinoma. However, it is unknown how this esophageal protection mechanism occurs[18,24,25].

### Hepatocellular carcinoma

There are about 1 million new cases of liver cancer each year, with hepatocellular carcinoma (HCC) responsible for most patients (90%) and the second most common cause of cancer death worldwide[26,27].

HCC presents a poor prognosis due to a late diagnosis. Multiple different tumors may occur in a single patient, leading to intra-tumor and intra-patient heterogeneity, which makes it difficult to establish a treatment line for HCC[27,28]. This heterogeneity can be caused by environmental factors and genomic and biological changes caused by the tumor lesion[27].

Cirrhosis and non-alcoholic fatty liver disease are risk factors associated with alcohol abuse and obesity that can lead to the onset of HCC. Genetic factors such as diabetes, exposure to carcinogens ( aflatoxins), and biological factors, especially hepatitis virus infection, can be highlighted[28].

The HCC development is a multistep process. It starts as a chronic liver disease that leads to inflammation, fibrosis, or aberrant hepatocyte regeneration. This set of conditions can progress to cirrhosis and later malignancy. The causes of this inflammation can be hepatitis B virus/hepatitis C virus infection, fatty liver disease, excessive alcohol intake, and aflatoxin consumption[26,29]. The outcome of this inflammation can be influenced by epigenetics and the immunological response in the tumor microenvironment to create a preneoplastic lesion until producing cells with highly proliferative, invasive, and survival skills[26].

The geographic regions most affected by HCC are Southeast Asia and sub-Saharan Africa, where there is endemic infection by the hepatitis virus and high exposure to aflatoxin, which are responsible for 70%-90% of cases in these places[28]. Currently, there is no line of therapy based on biomarkers suitable for HCC, although some candidate genes already exist[30].

### Pancreatic cancer

Pancreatic cancer, characterized by pancreatic ductal adenocarcinoma (PDAC), is the seventh leading cause of cancer-related deaths worldwide[31]. Its incidence is higher in Europe, followed by North America and Oceania, mainly in people over 70-years-old. Incidence and mortality increase with aging and are more common in men than women[32].

It is highly fatal because it presents aggressive growth and a lack of symptoms in the disease’s initial stage. As the tumor progresses, a picture of nonspecific symptoms begins, including jaundice, weight loss, abdominal pain, and fatigue[32]. About 80% of diagnoses are made in the advanced clinical stages, leading to a low 5-year prognosis of survival after surgery[33]. Surgical resection is the single strategy capable of curing pancreatic cancer. Besides, using chemotherapy concomitantly improves survival rates[34].

The main risk factors for the onset of pancreatic adenocarcinoma are smoking, alcohol, obesity, *H. pylori*, and type 2 diabetes[34]. Other factors, such as fat infiltration into the pancreas, have been associated with developing intraepithelial neoplasms. Pancreatic cancer can also arise from genetic
factors that can cause familial syndromes, such as Peutz-Jeghers syndrome[31]. A history of pancreatic cancer in first-degree relatives leads to a 2- to 3-fold increase in incidence risk due to inherited genetic predispositions[35].

**CRC**
CRC is the second most deadly cancer worldwide (1.3 million) and is the third leading cause of cancer-related deaths (540000) annually[2]. CRC is responsible for about 10% of cancer-related deaths worldwide, and in the last 45 years, there has been an increase in this mortality rate[36]. Its incidence is higher in developed countries such as Australia and New Zealand, followed by countries in Europe, East Asia, and North America. The frequency increases as individuals age, usually appearing in people over 50 years[37].

The tumor can originate in both the colon and the rectum. However, usually fuse because they have similar clinical and biological characteristics, with adenocarcinoma as the primary cell type of the tumor [37]. Many factors are associated with this increase in the diagnosis/mortality rate, such as an increase in life expectancy, poor dietary habits, and risk factors: smoking, red meat consumption, sedentary lifestyle, obesity, alcohol intake, and genetics[36,38-40]. These factors change the genetic/molecular in colon epithelial cells deactivating suppressor tumor genes and activating oncogenes to create aggressive and malignant behavior[40].

In the early stages, the disease has no clinical manifestation. The patient may be asymptomatic for years, but as the disease progresses, it advances to a more severe condition, with symptoms such as changes in intestinal motility, hidden or evident colorectal bleeding, cramps, loss of weight, weakness, and fatigue are manifesting[37].

**GENOME DATA IN GI CANCERS**

**EC**
There are several generalized genomic changes when esophageal carcinoma cells are analyzed. The most evident is a somatic mutation in tumor protein p53 (TP53) that appears in about 83% of cells. The p53 protein is a tumor suppressor and one of the most important transcription factors for regulating proliferation, apoptosis, autophagy, and cell cycle. However, this gene has a high mutation percentage in cancer cases, reaching 75% in tumor cells[12,41].

There are also changes in genes that control cell cycle and differentiation, including cyclin-dependent kinase inhibitor 2A (CDKN2A), nuclear factor erythroid derived 2-like 2, checkpoint kinase 1/2, and Notch1/3. Others may appear overexpressed such as cyclin D1 (CCND1) and CDK4/6[12,42-44]. The B cell translocation gene 3 protein can regulate the cell cycle’s progression; its low expression is related to the appearance of esophageal adenocarcinoma, and its expression level is directly correlated with lymph node metastasis[12,45].

The presence of mutations in the growth factors in cancer cells is well documented in the literature. Overexpression of epidermal growth factor receptor (EGFR) in carcinoma cells is associated with lymph node metastasis, and its expression level also influences the patient’s clinical stage. Another growth factor correlated with esophageal carcinoma is vascular endothelial growth factor C (VEGFC), encoded by the Fms related receptor tyrosine kinase 1 gene, and its levels in the tissues correlate with tumor stages and metastasis state[12,41].

Using next-generation sequencing, frequent mutations in carcinoma cells have been observed in the lysine methyltransferase 2D (KMT2D), SET domain containing 2 histone lysine methyltransferase, Notch1, retinoblastoma 1, CDKN2A, BRCA1-associated protein-1, forkhead box O3, and MutS homolog 6 (MSH6) genes compared to adenocarcinoma. It was also observed that some copy number variations in fibroblast growth factor 3 (FGF3), FGF4, FGF19, and CCND1 are more expressed in carcinoma compared to adenocarcinoma[46].

**GC**
Besides the infectious causes, the genetic data have helped to classify the GC into three additional subtypes: microsatellite instability (21.7%), genome stability (19.6%), and chromosome instability tumors (49.1%)[47].

Although infection is environmental, GC caused by infection is associated with genetic modifications such as phosphoinositide 3-kinase catalytic subunit (PIK3CA) mutations or gene amplification of Janus kinase (JAK), programmed death-ligand 1/2, or ERBB2. The infectious pathogen can also induce epigenetic modifications in this type of GC as DNA methylation in the phosphatase and tensin homolog (PTEN) gene promoter[48] and tumor-suppressor gene adenomatous polyposis coli (APC)[49]. Microsatellite instability is more associated with many truncating or missense mutations. The genes with the highest number of mutations in microsatellite instability GC are EGFR, ERBB3, KRAS/NRAS, and PIK3CA[50].
Genomically stable tumors present many mutations, especially genes well associated with cancer. The gene Ras homolog family member A works as signal transduction inducing cell proliferation, actin cytoskeleton structure, and cell movement associated with metastasis[51,52]. The genes claudin 18 and Rho-GTPase-activating proteins are frequently translocated in genomically stable GC tumors. The gene cadherin 1 (CDH1) encodes a cell-cell adhesion protein, which is also currently mutated in this type of cancer[53]. Furthermore, CDH1 has a role in cell proliferation, invasive behavior, and migration[54-56]. In the CDH1 gene, autosomal dominant mutations increase stomach cancer risk, especially when one of its copies is lost, generating a scenario of diffuse hereditary GC[18].

The chromosomal alterations involve gene amplification of EGFR, ERBB2/3, KRAS/NRAS, and RASA1; gene deletion of PTEN. These genetic modifications probably would result in gene activation or deactivation, which would result in tumor cell phenotypes. EGFR, ERBB2/3, JAK2, FGFR2, MET, KRAS/NRAS, and PIK3CA are predicted to be active, while RASA1, PTEN, and PIK3R1 would be inactive.

**HCC**

Numerous genetic changes in HCC cells, including mutations, changes in the number of copies, and chromosomal rearrangements, lead to a very complex genomic picture. Its complexity is further aggravated when etiological factors that precede the tumor development for years are considered[57]. Some genes play a fundamental role in cancer development, which is why they appear more frequently as TP53, MYC, WNT, and CTNNB1. Also highlighted are genes related to the cell cycle, such as CCND1 and CDKN2A[57].

A study integrating RNA sequencing, DNA sequencing, T cell receptor sequencing, and single nucleotide polymorphism array was carried out to investigate the space-time interactions between cancer and immune cells. A difference in the interaction of the adaptive immune system was detected in different regions of the same tumor. The TP53 and CTNNB1 genes expressed clonal mutations. High-level amplifications have been reported for CCND1, FGF19, and VEGFA. Mutations related to environmental risk factors such as smoking and alcohol were found in telomerase reverse transcriptase (TERT), CTNNB1, TP53, axin 1, and AT-rich interactive domain-containing protein 1A (ARID1A). There were also mutations without an apparent etiological factor in TERT, KMT2B, CCNA2, and CCNE1[58].

HCC results from of a multistep process involving genetic, epigenetic, and transcriptomic interactions. Among these interactions, epigenetics is among the most affected, leading to profound gene expression changes that can facilitate tumor formation The most common form of epigenetic silencing of tumor suppressor genes is hypermethylation of DNA. This epigenetic change usually occurs in CpG islands of gene-promoting regions such as deleted in liver cancer 1, tissue factor pathway inhibitor 2, CDKN2A, and PTEN[59].

**Pancreatic cancers**

The etiology of PDAC is mainly related to genetic predisposition, environmental factors such as smoking, obesity, and poor nutritional diet. These factors lead to chromosomal instability, affecting cell cycle pathways, chromatin remodeling, WNT, MYC, NOTCH signaling, and DNA damage repairs[35, 59]. Among the mutated genes, the one that appears most frequently is KRAS[60]. It is also possible to highlight mutations in MLH1, MSH2, PMS2, and MSH6 responsible for Lynch Syndrome and mutations in the germ lines of PALB2[35].

Pancreatic cancer genome analyses showed a homogenous profile with somatic mutations in a few genes shared KRAS, TP53, CDKN2A, and SMAD4. However, other less frequent genes are also involved including mitogen-activated protein kinase 4 (MAP2K4), lysine demethylase 6A, ring finger protein 43, ARID1A, transforming growth factor beta receptor 2 (TGFβR2), GNAS, Ras responsive element binding protein 1, and Polybromo 1[61-63]. These mutations can vary, and it is observed that non-silent mutations, gene amplification (> 8 copies, deletions, and structural variants)[63]. The set of genes that appear often mutated in pancreatic cancer plays a role in oncogenes, DNA damage repair, and chromatin modification[61,64]. The pancreatic cancer genome has chromosomal rearrangements classified into four subtypes: stable, locally rearranged, scattered, and unstable[61]. The mutation event more frequent is non-silent single nucleotide variants and copy number change (loss)[61]. The pancreatic cancer stable subtype was found in 20% of samples and had very few structural rearrangements (< 50 structural rearrangements) and more chromosomal mutations (aneuploidy). The locally rearranged subtype was found in 30% of samples with a high number of structural rearrangements (> 200) in a few chromosomes (three or fewer chromosomes), and there is more gene amplification. The scattered subtype is the most frequent (36% of samples) and has 50-200 structural rearrangements. Besides, the mutation type gene amplification is more frequent than in the other subtypes. The unstable subtype is less frequent (14% of the samples) and has the highest number of structural rearrangements (> 200 structural rearrangements), such as intrachromosomal, translocations, inversion, deletions, and duplication. Besides the frequent mutation described in pancreatic cancer, the unstable subtype is also associated with BReast CaNCer gene 1 (BRCA) pathway mutations (BRCA1, BRCA2, and PALB2)[61].
CRC

Most CRC cases are sporadic (70%), and only 30% are inherited[38]. The genes most affected are DNA mismatch-repair genes, APC, or mutY DNA glycosylase[39,40]. The DNA mismatch-repair proteins malfunctioning creates the condition of genetic mutation accumulation and tumor cells rising.

The CRC has three genetic subtypes based on their genomic alterations. The genomic alterations are chromosome or microsatellite instability or epigenetic changes of CpG islands (CpG island methylator phenotype - CIMP)[65,66]. Chromosomal instability is the most frequent in CRC, present in 71%-85%[65, 66]. The genetic differences also lead to overall survival differences in CRC. The CIMP subtype is associated with poor prognosis, followed by chromosome instability, and microsatellite instability showed the best survival[66-68]. The CIMP’s poor prognosis indicates the importance of CpG methylation dysregulation in CRC tumorigenesis. The methylation dysregulation might affect the proto-oncogenes and tumor-suppressor genes. The worst prognosis in the CIMP subtype indicates that a different approach is necessary to deal with molecular modifications. Epigenetic modifications can also be therapeutic targets to improve the treatment.

The genetic/genomic diversity in GI cancers shows the importance of molecular characterization to improve the treatment and prognosis.

PATHWAYS

The cellular pathways show the main functions and processes present in a cell when proteins work together. The cancer pathways are responsible for the cell’s behavior, allowing unlimited cell replication, survival, and tissue invasion. The pathways also are responsible for the molecular changes driving tumorigenesis. Understanding how a set of proteins work together to develop a cancer cell might point to the target proteins to block these processes.

The pathways most present among the GI cancers discussed here are apoptosis, focal adhesion, and p21-activated kinase (PAK), PI3K/Akt, TGF-β, and Toll-like receptor (TLR) signaling pathways (Table 2) [69-93].

Apoptosis plays a role in maintaining the balance in cell division and death during development and life. The unbalance of apoptosis leads to survival and uncontrolled division in tumorigenesis[94]. The apoptosis pathway is triggered by irreparable DNA damage, and it has many proteins that can fail and be blocked to inhibit cell death. The intrinsic process is mediated by mitochondria releasing cytochrome C after BH3 proteins activate B-cell lymphoma 2 (Bcl-2)-associated X protein and Bcl-2 homologous antagonist/killer. The cytochrome C and apoptotic protease activating factor 1, and caspase-9 create the apoptosome to continue the apoptosis process. The extrinsic process has death receptor ligands (cluster of differentiation 95 ligand [CD95L], TNF-related apoptosis-inducing ligand, and TNFα), death receptors, and associated proteins (Fas-associated death domain and TNF receptor 1-associated death domain protein) that transduce the death signal until caspase-8. Both intrinsic and extrinsic processes act on caspase-3/6/7 to induce the apoptosis cascade. Cell death by apoptosis results in a non-inflammatory process, which attracts research to the development of therapies that use apoptosis to treat cancer[95-97].

The PAK1 signaling pathway has six members divided into two groups and induces proliferation, survival, and motility[98]. PAK1 participates in cancer tumorigenesis after being highly expressed. The crosstalk of PAK1 with the MAPK/extracellular signal-regulated kinase (ERK) and PI3K/Akt pathways induces proliferation and survival, respectively[99]. PAK1 also connects with the Wnt signaling pathway through CTNNB1 and continues to stimulate growth and metastasis[98]. PAK1 expression protects the cell from apoptosis after interaction with Raf, which inactivates Bcl-2 family members (BCL2 associated agonist of cell death [BAD]) in mitochondria[98,100].

TLRs are part of the family of pattern knowledge receptors and operate on innate immunity, participating in the body’s first line of defense against invasion of microbial pathogens, tissue damage, and cancer. Its signaling pathway controls immune cell activation, maturation, and immune functions, especially the secretion of cytokines, influencing the tumor’s metabolism, proliferation, and spread [101]. They are expressed by several immune cells such as macrophages, dendritic cells, B lymphocytes, natural killer cells, non-immune cells such as epithelial cells, and cancer-associated fibroblasts[102]. When expressed in the tumor, TLRs can release cytokines and chemokines into the tumor environment to recruit other immune cells to release more proinflammatory cytokines, pro-angiogenic factors, and growth factors[101].

The TGF-β signaling pathways are pleiotropic, regulating multiple functions such as cell growth, differentiation, apoptosis, angiogenesis, motility, invasion, and immune response. Modifications in this pathway might play an essential role in developing tumors and metastasis. These modifications can affect not only the tumor cells but also the environment. At this level, the TGF-β generates an environment conducive to tumor growth and metastasis at all carcinogenesis stages. TGF-β has a contradictory behavior at the cellular level, acting as a suppressor and a tumor promoter[103,104]. Initially, the TGF-β pathway promotes cell cycle arrest and apoptosis. It promotes cancer cell motility, invasion, tumor progression, and metastasis in advanced stages. Thus, the accumulation of mutations is
Table 2 Pathways enriched in transcriptional analyses in esophageal, gastric, liver, pancreas, and colorectal cancers

| Pathway                              | CRC | EC | GC | HCC | PDAC | Ref.      |
|--------------------------------------|-----|----|----|-----|------|----------|
| Focal adhesion                       | X   | X  | X  | X   | X    | [69-76]  |
| Apoptosis                            | X   | X  | X  | X   | X    | [71,72,77-79] |
| PAK pathway                          | X   | X  | X  | X   | X    | [80-83]  |
| PI3K/Akt signaling pathway           | X   | X  | X  |     | X    | [71,84-86] |
| TGF-beta pathway                     | X   | X  | X  | X   | X    | [75,76,87-88] |
| Toll-like receptor signaling pathway | X   | X  | X  |     | X    | [88,91-93] |

CRC: Colorectal cancer; EC: Esophageal cancer; GC: Gastric cancer; HCC: Hepatocellular carcinoma; PAK: p21-activated kinase; PDAC: Pancreatic ductal adenocarcinoma; PI3K: Phosphoinositide 3-kinase; TGF: Transforming growth factor beta.

 responsible for guiding the evolution from a suppressor pathway to a tumor promoter[105].

The HCC RNA sequencing study identified four subtypes of HCC using 212 samples. The pathway analyses using the expression data reveal the enriched pathways metabolism RNA processes such as RNA processing, binding, and splicing. Although all the samples are from HCC, this result indicates different gene expression, cell activity, and behaviors. These enriched processes are not shared by the four HCC groups funded. However, at least three groups shared translation, ribosome, metabolism of proteins, and cytoplasm ribosomal proteins[106]. The microarray analysis using 25 HCC samples identified thousands of differentially expressed genes, and the pathways of cell cycle response, DNA damage response, cell survival, and apoptosis were identified. In addition, it was also linked to pathway terms and poor prognosis clinical parameters. These results also agree with RNA sequencing study point transcriptional regulation, RNA processing, and cell cycle regulation. The single-cell RNA sequencing analysis indicates 119 genes associated with HCC. The pathways analysis using Gene Ontology showed an acute inflammatory response, oxidative stress, and humoral response. Simultaneously, the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways indicate IL-17 and TNF signaling pathways, infectious disease, and rheumatoid arthritis. These samples present more immunological functions[107]. According to the OncoVar database, the KEGG pathways associated with HCC are mainly cancer pathways, viral infection, cell longevity (growth and death), antineoplastic drug resistance, and transduction signaling pathways (Wnt and Hippo signaling pathways)[108]. The molecular pathways in HCC are not entirely understood, and these results showed a notable variation of response in the differentially expressed genes working together to express a function.

Analysis combining CRC and endometrial cancer microarray samples identified 139 genes upregulated in both studies. These genes operate in the cellular functions of cell proliferation, Wnt signaling pathway, fatty acid beta-oxidation, transcription, exocytosis, dopaminergic neuron differentiation, and platelet degranulation. The KEGG pathways enriched were tight junctions, rheumatoid arthritis, renal cell carcinoma, and cancer pathways signaling. The rheumatoid arthritis pathway was enriched in more than one study with the genes (ATP6V0D1, ATP6V1D, CD28, CTLA4, CTSK, FOS, IL-18, and JUN)[109]. Other microarray meta-analysis studies using CRC samples point to also the KEGG pathways related to the cell cycle, pathways in cancer, and the Wnt signaling pathway. These pathways are linked; as a result, they share proliferation and block apoptosis[65]. Together, these processes induce the normal cell to convert to a tumor cell.

THE PROTEIN-PROTEIN INTERACTION IN CANCER

The number of GI cancer projects in different OMIC levels found many genes working in tumorigenesis. The GI cancers discussed here sum 178 different genes with associated mutations. The number of genes with mutations associated with GI cancers ranges from 41 to 89 genes in HCC and GC.

Each of these cancers has variation and can be classified into subtypes according to cell origin, chromosomal structural rearrangements, gene expression, and cell behaviors. However, there are 46 genes shared by at least two types of cancers. These genes should be investigated to understand better how they assist in the cell transformations to tumors, biomarkers of tumor cells, and potential drug or therapy targets. The genes present in all five types of cancers are activin A receptor type 2A, APC, ARID1A, and CTNNB1.

We used information from STRING database to check the protein-protein interaction (PPI) from these 178 genes. We used the experimental information only to build this PPI network. The PPI investigation allows for building a network with 111 genes connected (Figure 1)[110]. The number of nodes in the PPI network indicates that these genes work together in GI cancer tumorigenesis.
Bispo IMC et al. Overview of gastrointestinal cancer OMIC data

Figure 1 Protein-protein interaction of genes with mutations associated with gastrointestinal cancers. The nodes represent the genes, and the edges represent the protein interactions. The network was built using information from experimental data only from the STRING database[110]. The node size represents the number of protein interactions (degree), indicating the node’s centrality.

We analyzed the GI cancer network to identify in this PPI most connected protein (high degree) as central nodes. The proteins CTNNB1, Akt1, TP53, EP300, and TP53-binding protein 1 (53BP1) are the central nodes with the highest degree.

The CTNNB1 gene encodes a beta-catenin protein expressed in the adherens junctions[53]. The beta-catenin is a cytoplasm protein that works in the adhesion between cells. The beta-catenin binds the actin in the cytoskeleton and the E-cadherin protein in the cell membrane, connecting neighboring cells[111]. The beta-catenin is also a mediator in the Wnt signaling pathway. When activated, the Wnt signaling pathway induces the accumulation of beta-catenin in the nucleus, activating target genes' transcription[53]. The WNT protein binds the receptor in the membrane and induces beta-catenin to accumulate, promoting cell survival and proliferation[65]. The mutations in CTNNB1 gene are frequently found in HCC (13%)[112,113], CRC (6%)[114], and it is mutated in 4% of GC[47].

The Akt1 is a central protein in cell transduction signaling, which, when induced by PI3K, induces process cell proliferation, survival, and angiogenesis. The activation of the mammalian target of rapamycin (mTOR) complex by ATK is investigated as a drug target to treat PDAC[115-117]. The Epstein-Barr virus and H. pylori induce inflammation and the expression of Akt in GC. The outcome is cell proliferation and telomerase activation[118,119]. The investigation of blockage of Akt in GC resulted in suppression of growth and metastasis[120]. The investigation of critical proteins in HCC PPI identified several functions crucial in tumorigenesis, cell proliferation, anti-apoptosis, and metastasis.
The PPI network showed Akt1 as a potential drug target[104]. These results indicate Akt1 central position in tumorigenesis and a potential drug target.

The 53BP1 protein has a role in DNA damage response and cycle arrest, triggering the expression of p53; the malfunctioning of this protein might lead to the development of genomic instability and molecular diseases. The lack of function of 53BP1 is associated with poor prognosis, angiogenesis, and metastasis[121]. The decreased expression of 53BP1 in CRC induces radiotolerance and chemoresistance. Moreover, CRC cells with lower expression of 53BP1 have a higher proliferating rate, decreased apoptosis, and poor prognosis[122-124]. The 53BP1 also interacts with p53, as indicated in CRC and EC, when the reduction of 53BP1 induces the downregulation of p53[122,123,125]. The 53BP1 is expressed as soon as DNA damage treatment occurs in human pancreatic cells[126]. The 53BP1 might also influence tumor outcome in pancreatic cancer, as shown when the variation of 53BP1 expression changes the association of carbohydrate 19-9, a well-known pancreatic cancer marker, and overall survival[100].

The p300 protein (encoded by the EP300 gene) is a histone acetyltransferase that participates in chromatin remodeling and interacts with basal transcriptional machinery to improve DNA binding, affecting gene transcription in normal and cancer cells[127]. The EP300 mutations are common in CRC and GC by frameshift in microsatellite regions[128]. The mutation in EP300 is frequent in EC (10%), and it correlates with a poor prognosis, associated with cell proliferation, migration, and invasion (metastasis)[129,130]. The role of p300 in remodeling the chromatin makes it appropriate to investigate epigenetic therapies, and the use of natural nutrients as potential prevention and treatment has already been discussed with GC[131].

### ESSENTIAL GENES AND KAPLAN-MEIER SURVIVAL ANALYSIS

All GI cancers discussed here have a low 5-year survival rate, except CRC (Table 1). The esophagus, liver, and pancreas have the lowest 5-year survival rate. The late diagnosis, metastasis, and aggressive behavior are associated with a low 5-year survival rate. Many studies describe the poor prognosis as associated with gene expression[97,122,129,132-135].

The expression levels are crucial information that might work as a prognostic factor in GI cancers. The association between TP53BP1 expression and overall survival analyses in CRC indicate a connection with low expression and low survival in the I-IIA stage, T3-T4, and N0[122]. Again, this protein has an essential role in CRC, not only to a high degree but also as a prognostic marker. The EP300 gene has high expression associated with poor survival in ESCC[129]. The long non-coding RNAs (IncRNAs) have a critical role in cancer development, and the high expression of ANRIL and homeobox A11-antisense RNA (HOXA11-AS) IncRNA is associated with poor survival in GC[132,133]. The overexpression of IncRNA ANRIL is significantly associated with GC progression and can serve as an independent predictor of patient survival[136]. The high expression of ANRIL combined with polycymb repressive complex 2 significantly silences microRNA 99a (miR-99a) and miR-449a at the transcriptional level, which increases the expression of mTOR, CDK6, and E2 transcription factor 1[132]. The HOXA11-AS gene reduces the expression of suppressor tumor genes Krüppel-like Factor 2 (KLF2) and protease serine 8 at the transcriptional level[133]. KLF2 downregulation is associated with migration, invasion, and poor survival[137,138]. KLF2 inhibits growth and migration and induces pancreatic cancer cells to senescence.

ESCC has poor survival when low esophageal cancer-related gene 4 expression occurs compared to the high-expression group[139]. EAC has worse overall survival when IL11 expression increases. Poor survival is also observed in a low expression of neuronal pentraxin 1, inositol 1,4,5-trisphosphate receptor type 1, and platelet derived growth factor D[140].

PDAC analyses show that the highest expression of the centromere protein F, sciellin, serpin family B member 5, solute carrier family 2 member 1 (SLC2A1), SLC6A14, transmembrane channel like 7, and transmembrane serine protease 4 is associated with a lower probability of survival compared to the same genes in low expression[141].

We investigated the gene expression and overall survival of the central genes present in the PPI network (Figure 1). We used information from the Kaplan Meier plotter (https://kmplot.com)[142] to investigate the potential prognosis of the central genes. Three of the five genes investigated have gene expression associated with survival (Akt1, TP53, and CTNNB1) (Figure 2).

The high expression of Akt1 and TP53 in GC is associated with a poor prognosis. In contrast, low CTNNB1 expression is correlated with reduced survival. The expression values and survival curves for TP53 (mRNA) in the Kaplan Meier plotter agree with tumor protein p53 expression in GC[143,144]. The TP53 expression is low and has a short half-life in normal cells, whereas in tumor cells, this gene has high expression and a long half-life[145]. The higher expression of TP53 is indicative of the worst prognosis. Akt1 expression was not indicative of prognosis[146]. However, they found that EGFR and Akt1 expression are mutually exclusive and associated with poor survival. This result might be due to the two proteins acting in the same pathway. The phosphorylated Akt1 and CTNNB1 high expression are associated with poor survival[147,148].
There is no significant difference between Akt1 or CTNNB1 high and low expression groups in liver cancer. Regarding the TP53 gene, the differences in expression are not significant in the initial stage of carcinoma. However, this high expression predicts a poor prognosis and a higher mortality rate than a low expression. The results are not according to the TP53 gene expression for HCC, where TP53 high expression is present in poor prognosis groups[149].

However, the prognosis markers based on expression have limitations, and the result must be taken together with other markers.

CONCLUSION
The OMIC information about GI cancer is very complex, and each organ/region has subtypes and particularities. We presented information about and brought to light the most common genomic changes among these cancers. The pathways shared by these molecular diseases also point to the standard functions and the crosstalk of these pathways and the PAK1 pathway centrality, connecting to MAPK/ERK, PI3K/Akt, apoptosis, and Wnt signaling pathways. The PPI network pointed to five central genes, and the literature corroborates the crucial role in GI cancer with expression and poor prognosis association. This information might help in the target choice of drug and therapy research.

FOOTNOTES
Author contributions: Bispo IMC, Granger HP, and de Freitas LM wrote the paper; Almeida PP collected the data and contributed to the analyses; Nishiyama PB and de Freitas LM revised the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: Brazil

ORCID number: Jasmin Moreira Costa Bispo 0000-0001-7500-619X; Henry Paul Granger 0000-0002-4889-8732; Palloma Porto Almeida 0000-0002-1588-8722; Patricia Belini Nishiyama 0000-0002-9495-6171; Leandro Martins de Freitas 0000-0003-4327-2922.

S-Editor: Gong ZM
L-Editor: Filipodia
P-Editor: Gong ZM

REFERENCES

1. Ferlay J. Global Cancer Observatory: Cancer Today. 2020 [cited 2021-02-05] Available from: https://gco.iarc.fr/today/about
2. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019; 144: 1941-1953 [PMID: 30330310 DOI: 10.1002/ijc.31937]
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70: 7-30 [PMID: 31912902 DOI: 10.3322/caac.21590]
4. Malhotra GK, Yanala U, Ravipati A, Follet M, Vijayakumar M, Are C. Global trends in esophageal cancer. J Surg Oncol 2017; 115: 564-579 [PMID: 28302055 DOI: 10.1002/so.20459]
5. Gupta B, Kumar N. Worldwide incidence, mortality and time trends for cancer of the oesophagus. Eur J Cancer Prev 2017; 26: 107-118 [PMID: 27014938 DOI: 10.1097/CEJ.0000000000000249]
6. Arnold M, Laversanne M, Brown LM, Devesa SS, Bray F. Predicting the Future Burden of Esophageal Cancer by Histological Subtype: International Trends in Incidence up to 2030. Am J Gastroenterol 2017; 112: 1247-1255 [PMID: 28585555 DOI: 10.1038/ajg.2017.155]
7. Middleton DRS, Bouaoun L, Hanisch R, Bray F, Dzamaalala C, Chasimphwa M, Sinya D, Mbalawa CG, N'Da G, Woldegeorgis MA, Njie R, Koulibaly M, Buziba N, Ferro J, Njouou H, Ogunbiyi F, Wabinga HR, Chokunonga E, Bokor MZ, Korir AR, Mwasamwaja AO, Mmbaga BT, Schüz J, McCormack VA. Esophageal cancer male to female incidence ratios in Africa: A systematic review and meta-analysis of geographic, time and age trends. Cancer Epidemiol 2018; 53: 119-128 [PMID: 29414631 DOI: 10.1016/j.canep.2018.01.020]
8. Abnet CC, Arnold M, Wei WQ. Epidemiology of Esophageal Squamous Cell Carcinoma. Gastroenterology 2018; 154: 360-373 [PMID: 28823862 DOI: 10.1053/j.gastro.2017.08.023]
9. Abbas G, Krasna M. Overview of esophageal cancer. Ann Cardiothorac Surg 2017; 6: 131-136 [PMID: 28447001 DOI: 10.21037/acs.2017.03.03]
10. Alsop BR, Sharma P. Esophageal Cancer. Gastroenterol Clin North Am 2016; 45: 399-412 [PMID: 27546839 DOI: 10.1016/j.gtc.2016.04.001]
11. Hesari A, Azizian M, Sheikhi A, Nesaei A, Sanaei S, Mahinparvar N, Derakhshani M, Hedayt P, Ghasemi F, Mirzaei H. Chemopreventive and therapeutic potential of curcumin in esophageal cancer: Current and future status. Int J Cancer 2019; 144: 1215-1226 [PMID: 30362511 DOI: 10.1002/ijc.31937]
12. Huang FL, Yu SJ. Esophageal cancer: Risk factors, genetic association, and treatment. Asian J Surg 2018; 41: 210-215 [PMID: 27986415 DOI: 10.1016/j.asjsur.2016.10.005]
13. Salimian KJ, Waters KM, Eze O, Pezhov MH, Tarabishy Y, Shin EJ, Canto MI, Voltzgge L, Montgomery EA. Definition of Barrett Esophagus in the United States: Support for Retention of a Requirement for Goblet Cells. Am J Surg Pathol 2018; 42: 264-268 [PMID: 29016405 DOI: 10.1097/PAS.0000000000000971]
14. Solanky D, Krishnamoorthi R, Crews N, Johnson M, Wang K, Wolfsen H, Fleischner D, Ramirez FC, Katzka D, Buttar N, Iyer PG. Barrett Esophagus Length, Nodularity, and Low-grade Dysplasia are Predictive of Progression to Esophageal Adenocarcinoma. J Clin Gastroenterol 2019; 53: 361-365 [PMID: 29608452 DOI: 10.1097/MCG.0000000000001027]
15. Horig Y, Yoshio T, Aoyama K, Yoshimizu S, Horichi Y, Ishiyama A, Hirasa T, Tsuchida T, Ozawa T, Ishihara S, Kunugai Y, Fujishiro M, Maetani I, Fujisaki J, Tada T. Diagnostic outcomes of esophageal cancer by artificial intelligence using convolutional neural networks. Gastrointest Endosc 2019; 89: 25-32 [PMID: 30120958 DOI: 10.1016/j.gie.2018.07.037]
16. Machowska I, Baj I, Sitarz M, Maciejewski R, Sitarz R. Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies. Int J Mol Sci 2020; 21 [PMID: 32512697 DOI: 10.3390/ijms21114102]
17. Boland CR, Yurgelun MB. Historical Perspective on Familial Gastric Cancer. Cell Mol Gastroenterol Hepatol 2017; 3: 192-200 [PMID: 28275686 DOI: 10.1016/j.jcmgh.2016.12.003]
18. Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol 2019;
14. Yusefi AR, Bagheri Lankarani K, Bastani P, Radimnaneshe M, Kavosi Z. Risk Factors for Gastric Cancer: A Systematic Review. *Asian Pac J Cancer Prev* 2018; 19: 591-603 [PMID: 29579788 DOI: 10.21037/apjcp.2018.19.3.591]

15. Sánchez-Zaunz N, Torres J, Gómez A, Camorlinga-Ponce M, Muñoz-Pérez L, Herrera-Goeppert F, Medrano-Guzmán R, Giono-Cerezo S, Maldonado-Bernal C. Circulating blood levels of IL-6, IFN-γ, and IL-10 as potential diagnostic biomarkers in gastric cancer: a controlled study. *BMC Cancer* 2017; 17: 384 [PMID: 28558708 DOI: 10.1186/s12885-017-3310-9]

16. Ramis IB, Vianna JS, Gonçalves CV, von Groll A, D dallagostin OA, da Silva PEA. Polymorphisms of the IL-6, IL-8 and IL-10 genes and the risk of gastric pathology in patients infected with Helicobacter pylori. *J Microbiol Immunol Infect* 2017; 50: 153-159 [PMID: 25883819 DOI: 10.1016/j.jmii.2015.03.002]

17. Arachchi PS, Fernando N, Weerasekara MM, Seneviratne B, Weerasekara DD, Gunasekara CP. Proinflammatory Cytokine IL-17 Shows a Significant Association with Helicobacter pylori Infection and Disease Severity. *Gastroenterol Res Pract* 2017; 2017: 6265150 [PMID: 29391865 DOI: 10.1155/2017/6265150]

18. International Agency for Research on Cancer (IARC). Infection with Helicobacter pylori. In: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group, Lyon, France. 1994: 177-240

19. Moss SF. The Clinical Evidence Linking Helicobacter pylori to Gastric Cancer. *Cell Mol Gastroenterol Hepatol* 2017; 3: 183-191 [PMID: 28275681 DOI: 10.1016/j.jmgh.2016.12.001]

20. Choi JJ, Kim CG, Lee JY, Kim YJ, Kook MC, Park B, Joo J. Family History of Gastric Cancer and Helicobacter pylori Treatment. *N Engl J Med* 2020; 382: 427-436 [PMID: 31995688 DOI: 10.1056/NEJMoa1909666]

21. Villanueva A. Hepatocellular Carcinoma. *N Engl J Med* 2019; 380: 1450-1462 [PMID: 36970190 DOI: 10.1056/NEJMra1713263]

22. Liu J, Deng H, Wang XW. The significance of infiltrating and intratumor heterogeneity in liver cancer. *Exp Mol Med* 2018; 50: e416 [PMID: 29305312 DOI: 10.1038/s41198-017.165]

23. Rao CV, Ash AS, Yamada HY. Frequently mutated genes/pathways and genomic instability as prevention targets in liver cancer. *Carcinogenesis* 2017; 38: 2-11 [PMID: 27838634 DOI: 10.1093/carcin/bgw118]

24. Tunissiolli NM, Castanhole-Nunes MMU, Biselli-Chicote PM, Pavarino EC, da Silva RF, da Silva RC, Goloni-Bertollo EM. Hepatocellular Carcinoma: a Comprehensive Review of Biomarkers, Clinical Aspects, and Therapy. *Asian Pac J Cancer Prev* 2017; 18: 863-872 [PMID: 28545181 DOI: 10.22034/apjcp.2017.18.4.863]

25. Chen M. Wei L, Law CT, Tsang FH, Shen J, Cheng CL, Tsang LH, Ho DW, Chiu DK, Lee JM, Wong CC, Ng IO, Wong CM. RNA N6-methyladenosine methyltransferase-1 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. *HEPATOLOGY 2018; 67: 2254-2270 [PMID: 29171881 DOI: 10.1002/hep.29683]"

26. Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. *Lancet* 2020; 385: 209-2020 [PMID: 32593337 DOI: 10.1016/S1474-4422(20)30974-0]

27. Rawla P, Sunkara T, Gadupati V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. *World J Oncol* 2019; 10: 10-27 [PMID: 30830448 DOI: 10.14740/wjovn1166]

28. Pietras D, Pécuchet N, Garlan F, Dideolot A, Dubreuil O, Doat S, Imbert-Bismut F, Karoui M, Vaillant JC, Taly V, Laurent-Puig P, McWilliams RR, Majithia N, Allen BA, Kidd J, Singh N, Hartman AR, Petersen GM. Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history. *Genet Med 2018; 20: 119-127 [PMID: 28726808 DOI: 10.1038/gim.2017.85]]

29. Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. *Paz Gastroenterol* 2019; 14: 89-103 [PMID: 31615222 DOI: 10.5114/pg.2018.81072]

30. Mattiucci C, Sanchis-Gomar F, Lippi G. Concise update on colorectal cancer epidemiology. *Ann Transl Med* 2019; 7: 609 [PMID: 32047770 DOI: 10.21037/atm.2019.07.91]

31. Hadjitetrou A, Anyfantakis D, Galanakis CG, Kastanakis M, Kastanakis S. Colorectal cancer, screening and primary care: A mini literature review. *World J Gastroenterol* 2017; 23: 6049-6058 [PMID: 28970720 DOI: 10.3748/wjg.v23.i33.6049]

32. Mármon I, Sánchez-de-Diego C, Pradilla Díaz A, Cerrada E, Rodríguez Yoldi MJ. Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer. *Int J Mol Sci* 2017; 18 DOI: 10.3390/ijms18101971

33. Kuijpers EJ, Grady WM, Lieberman D, Seufferlein T, Sung JJ, Boelens PG, van de Velde CJ, Watanabe T. Colorectal cancer. *Nat Rev Dis Primers* 2015; 2015: 15065 DOI: 10.1038/nrdp.2015.65]

34. Wong Z, Li C, Li Y, Guo X, Yan Z, Gao F. DpdbA-Induced Growth Inhibition in Human Esophageal Cancer Cells Involved Inactivation of the p53/EGFR/akt Pathway. *Oxid Med Cell Longev* 2019; 2019: 5414670 [PMID: 31354907 DOI: 10.1155/2019/5414670]

35. Cuzzoloi CI. Castanhole-Nunes MMU, Pavarino EC, Goloni-Bertollo EM. MicroRNAs as regulators of VEGFA and NFɛ22L2 in cancer. *Gene* 2020; 759: 144994 [PMID: 32721475 DOI: 10.1016/j.gene.2020.144994]

36. Li Y, Xiao F, Li W, Hu P, Xu R, Li J, Li G, Zhu C. Oveexpression of Opa interacting protein 5 increases the progression of liver cancer via BMPR2/JUN/CHEK1/RAC1 dysregulation. *Oncol Rep* 2019; 41: 2075-2088 [PMID: 30816485 DOI: 10.3892/or.2019.7006]

37. Natsuzaka M, Whelan KA, Kagawa S, Tanaka K, Giroux V, Chandramouleeswaran PM, Long A, Sahu V, Darling DS, Que J, Yang Y, Katz JP, Wileyto EP, Basu D, Kita Y, Natsugoe S, Nagamura S, Klein-Szanto AJ, Diehl J, Bass AJ, Wong KK, Rustgi AK, Nakagawa H. Interplay between Notch1 and Notch3 promotes EMT and tumor initiation in squamous cell carcinoma. *Nat Commun* 2017; 8: 1758 [PMID: 29170450 DOI: 10.1038/s41467-017-01500-9]
Bispo IMC et al. Overview of gastrointestinal cancer OMIC data

45. Zhang F, Zhang M. Olearuepin induces esophageal cancer through hypoxic suppression of BTG3 mRNA. Food Funct 2019; 10: 978-985 [PMID: 30702111 DOI: 10.1039/c9fo02236b]

46. Salem ME, Puccini A, Xiu J, Raghavan D, Lenz HJ, Korn WM, Shields AF, Philip PA, Marshall JL, Goldberg RM. Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma. Oncologist 2018; 23: 1319-1327 [PMID: 29866946 DOI: 10.1634/theoncologist.2018-0143]

47. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; 513: 202-209 [PMID: 25079317 DOI: 10.1038/nature13486]

48. Ebrahimi V, Soleimanian A, Ebrahimi T, Azargun R, Yazdani P, Eyvaz S, Tarhiza V. Epigenetic modifications in gastric cancer: Focus on DNA methylation. Gene 2020, 742: 144577 [PMID: 32171825 DOI: 10.1016/j.gene.2020.144577]

49. Zhou X, Jiao D, Dou M, Zhang W, Hua H, Chen J, Li Z, Li L, Han X. Association of APC gene promoter methylation and the risk of gastric cancer: A meta-analysis and bioinformatics study. Medicine (Baltimore) 2020; 99: e19828 [PMID: 32312003 DOI: 10.1097/MD.0000000000019828]

50. Matsuoka T, Yashiro M. Biomarkers of gastric cancer: Current topics and future perspective. World J Gastroenterol 2018; 24: 2818-2832 [PMID: 30018477 DOI: 10.3748/wjg.v24.i26.2818]

51. Kong R, Yi F, Wen P, Liu J, Chen X, Ren J, Li X, Shang Y, Nie Y, Wu K, Fan D, Zhu L, Feng W, Wu JY. Myo9b is a key player in SLIT/ROBO-mediated lung tumor suppression. J Clin Invest 2015; 125: 4407-4420 [PMID: 26529257 DOI: 10.1172/JCI81673]

52. Chen Y, Yang Z, Meng M, Zhao Y, Dong N, Yang H, Liu L, Ding M, Peng HB, Shao F. Cullin mediates degradation of RhoA through evolutionarily conserved BTB adaptors to control actin cytoskeleton structure and cell movement. Mol Cell 2009; 35: 841-855 [PMID: 19782033 DOI: 10.1016/j.molcel.2009.09.004]

53. Tang Y, Liu Z, Zhao L, Clemens TL, Cao X. Smad7 stabilizes beta-catenin binding to E-cadherin complex and promotes cell-cell adhesion. J Biol Chem 2008; 283: 23956-23963 [PMID: 18593710 DOI: 10.1074/jbc.M803512200]

54. Lin G, Aranda V, Muthuswamy SK, Tonks NK. Identification of PTPN23 as a novel regulator of cell invasion in mammary epithelial cells from a loss-of-function screen of the ‘PTPome’. Genes Dev 2011; 25: 1412-1425 [PMID: 21724833 DOI: 10.1101/gad.201891.1]

55. Lorger M, Moelling K. Regulation of epithelial wound closure and intercellular adhesion by interaction of AF6 with actin cytoskeleton. J Cell Sci 2006; 119: 3385-3398 [PMID: 16588264 DOI: 10.1242.jcs.03027]

56. Jesse S, Koenig A, Ellenrieder Y, Menke A. Lef-1 isoforms regulate different target genes and reduce cellular adhesion. Int J Cancer 2010; 126: 1109-1120 [PMID: 19653274 DOI: 10.1002/ijc.25802]

57. Castelli G, Pelosi E, Testa U. Liver Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. Cancers (Basel) 2017; 9: [PMID: 28930164 DOI: 10.3390/cancers9090127]

58. Sia D, Villanueva A, Friedman SL, Llovet JM. Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis. Gastroenterology 2017; 152: 745-761 [PMID: 28043904 DOI: 10.1053/j.gastro.2016.11.048]

59. Knudsen ES, Balaji U, Mannakee B, Vail P, Eslinger C, Moxom C, Mansour J, Witiwickz AK. Pancreatic cancer cell lines as patient-derived avatars: genetic characterization and functional utility. Gut 2018; 67: 508-520 [PMID: 28073890 DOI: 10.1136/gutjnl-2016-313133]

60. Waters AM, Der CJ. KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med 2018; 8 [PMID: 25292660 DOI: 10.1101/cshperspect.a014335]

61. Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quack K, Quinn MC, Robertson AJ, Fadlullah MZ, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Nourbakhsh E, Wani S, Wilson PJ, Markham E, Cloonan N, Anderson MJ, Fink JL, Holmes O, Kazakoff SH, Leonard C, Newell F, Poudel B, Song S, Taylor D, Waddell N, Wood N, Xu Q, Wu J, Pinese M, Cowley MJ, Lee HC, Jones MD, Nagrial AM, Humphris J, Chantry LA, Chin V, Steinmann AM, Mawson A, Humphrey ES, Colvin EK, Chou A, Scarlett CJ, Pinho AV, Giry-Laterriere M, Rooman I, Samra JS, Kench JG, Pettit JA, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N, Jamieson NB, Graham JS, Niclou SP, Bjerkvig R, Grützmann R, Aust D, Hruban RH, Maitra A, Iacobuzio-Dobson CA, Wolfgang CL, Morgan RA, Lawlor RT, Corbo V, Bassi C, Falconi M, Zamorti G, Tortora G, Tempero MA; Australian Pancreatic Cancer Genome Initiative, Gill AJ, Esahleman JR, Pilsarky C, Scarpa A, Musgrove EA, Pearson JV, Birkman AV, Grimmmond SM. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 2015; 518: 495-501 [PMID: 25571966 DOI: 10.1038/nature14169]

62. Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, Miller DK, Christ AN, Bruxner TJ, Quinn MC, Nourse C, Murtaugh LC, Harliwong I, Idrisoglu S, Manning S, Nourbakhsh E, Wani S, Fink L, Holmes O, Chin V, Anderson MJ, Kazakoff S, Leonard C, Newell F, Waddell N, Wood S, Xu Q, Wilson PJ, Cloonan N, Kassahn KS, Taylor D, Quack K, Robertson AJ, Pantano L, Mincarelli AM, Sanchez LN, Evers L, Wu J, Pinese M, Cowley MJ, Jones MD, Colvin EK, Nagrial AM, Humphrey ES, Chantry LA, Mawson A, Humphris J, Chou A, Pajic M, Scarlett CJ, Pinho AV, Giry-Laterriere M, Rooman I, Samra JS, Kenc JG, Lovell JA, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N, Jamieson NB, Graham JS, Niclou SP, Bjerkvig R, Grützmann R, Aust D, Hruban RH, Maitra A, Iacobuzio-Dobson CA, Wolfgang CL, Morgan RA, Lawlor RT, Corbo V, Bassi C, Falconi M, Zamorti G, Tortora G, Tempero MA; Australian Pancreatic Cancer Genome Initiative, Gill AJ, Esahleman JR, Pilsarky C, Scarpa A, Musgrove EA, Pearson JV, Birkman AV, Grimmmond SM. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 2015; 518: 495-501 [PMID: 25571966 DOI: 10.1038/nature14169]

63. Collisson EA, Bailey P, Chang DK, Birkman AV. Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol 2019; 16: 207-220 [PMID: 30718832 DOI: 10.1038/s41575-019-0140-x]

64. Cancer Genome Atlas Research Network. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell 2017; 32: 185-203 [PMID: 28810144 DOI: 10.1016/j.ccell.2017.07.007]

65. Centelles JJ. General aspects of colorectal cancer. ISRN Oncol 2012; 2012: 139268 [PMID: 23209942 DOI: 10.5402/2012/139268]

66. Simons CC, Hughes LA, Smits KM, Khalid-de Bakker CA, de Bruijne AP, Carvalho B, Meijer GA, Schouten LJ, van den Brandt PA, Weijenberg MP, van Engeland M. A novel classification of colorectal tumors based on microsatellite
instability, the CpG island methylator phenotype and chromosomal instability: implications for prognosis. Ann Oncol 2013; 24: 2048-2056 [PMID: 23532114 DOI: 10.1093/annonc/mdt076]

67. Phripps AI, Limburg PJ, Baron JA, Burnett-Hartman AN, Weisenberger DJ, Laird PW, Sinicrope FA, Rosty C, Buchanan DD, Potter JD, Newcomb PA. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology 2015; 148: 77-87.e2 [PMID: 25280443 DOI: 10.1053/j.gastro.2014.09.038]

68. Wielandt AM, Hurtado C, Moreno C M, Villarreal C, Castro M, Estay M, Simian D, Martinez M, Vial MT, Kronberg U, López-Kóstner F. Characterization of Chilean patients with sporadic colorectal cancer according to the three main carcinogenic pathways: Microsatellite instability, CpG island methylator phenotype and Chromosomal instability. Tumour Biol 2020; 42: 1010423820938492 [PMID: 32653826 DOI: 10.1080/10428328.2020.1894263]

69. Dai F, Mei L, Meng S, Ma Z, Guo W, Zhou J, Zhang J. The global expression profiling in esophageal squamous cell carcinoma. Genomics 2017; 109: 241-250 [PMID: 28442363 DOI: 10.1016/j.ygeno.2017.04.005]

70. Zhang C, Peng L, Zhang Y, Liu Z, Li W, Chen S, Li G. The identification of key genes and pathways in hepatocellular carcinoma by bioinformatics analysis of high-throughput data. Med Oncol 2017; 34: 101 [PMID: 28432618 DOI: 10.1007/s12032-017-0963-9]

71. Zhou W, Wu Z, Zhang J, Liu X, Guo S, Jia S, Zhang X, Zhu Y, Wang M. Integrated bioinformatics analysis to decipher molecular mechanism of compound Kushen injection for esophageal cancer by combining WGCNA with network pharmacology. Sci Rep 2020; 10: 12745 [PMID: 32728182 DOI: 10.1038/s41598-020-69708-2]

72. Nam S, Park T. Pathway-based evaluation in early onset colorectal cancer suggests focal adhesion and immunosuppression along with epithelial-mesenchymal transition. PLoS One 2012; 7: e31685 [PMID: 22496728 DOI: 10.1371/journal.pone.0031685]

73. Gu C, Wang X, Long T, Zhong Y, Ma Y, Hu Z, Li Z. FSTL1 interacts with VIM and promotes colorectal cancer metastasis via activating the focal adhesion signalling pathway. Cell Death Dis 2018; 9: 654 [PMID: 29844309 DOI: 10.1038/s41419-018-0695-6]

74. Donahue TR, Tran LM, Hill R, Li Y, Kovochich A, Calvopina HH, Patel SG, Wu N, Hindoyan A, Farrell JJ, Li X, Dawson DW, Wu H. Integrative survival-based molecular profiling of human pancreatic cancer. Clin Cancer Res 2012; 18: 1352-1363 [PMID: 22261810 DOI: 10.1158/1078-0432.CCR-11-1539]

75. Badea I, Herlea V, Dinu SO, Dumitrascu T, Popescu I. Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia. Hepatogastroenterology 2008; 55: 2016-2027 [PMID: 19260470]

76. Wu J, Zhao X, Lin Z, Shao Z. A system level analysis of gastric cancer across tumor stages with RNA-seq data. Mol Biosyst 2015; 11: 1925-1932 [PMID: 25924093 DOI: 10.1039/c5mb00105f]

77. Akbari F, Peymani M, Salehzadeh A, Ghaedi K. Integrative in silico and in vitro transcriptomics analysis revealed new lncRNAs related to intrinsic apoptotic genes in colorectal cancer. Cancer Cell Int 2020; 20: 546 [PMID: 33292233 DOI: 10.1186/s12935-020-01633-w]

78. Zhang W, Liu S, Zhan H, Yan Z, Zhang G. Transcriptome sequencing identifies key pathways and genes involved in gastric adenocarcinoma. Mol Med Rep 2018; 18: 3673-3682 [PMID: 30106143 DOI: 10.3892/mmr.2018.9370]

79. Hao Y, Zhang J, Shan G, Zhang N, Jin W, Nan K. Establishment of optimal regulatory network of colorectal cancer based on p24.3 protein. Saudi J Biol Sci 2017; 24: 1781-1786 [PMID: 29551923 DOI: 10.1515/sjbs-2017.11.012]

80. Mahlamiiki EH, Kautzaniemi P, Monni O, Wolf M, Hautaniemi S, Kallioniemi A. High-resolution genomic and expression profiling reveals 105 putative amplification target genes in pancreatic cancer. Neoplasia 2004; 6: 432-439 [PMID: 15548351 DOI: 10.1593/neo.04130]

81. Fang ZP, Jiang BG, Gu XF, Zhao B, Ge RL, Zhang FB. P21-activated kinase 5 plays essential roles in the proliferation and tumorigenicity of human hepatocellular carcinoma. Acta Pharmacol Sin 2014; 35: 82-88 [PMID: 23685956 DOI: 10.1038/aps.2013.31]

82. Chen H, Miao J, Li H, Wang C, Li J, Zhu Y, Wang J, Wu X, Qiao H. Expression and prognostic significance of p21-activated kinase 6 in hepatocellular carcinoma. J Surg Res 2018; 189: 81-88 [PMID: 24576777 DOI: 10.1016/j.jss.2018.01.049]

83. Huang S, Zhu Y, Wang C, Li X, Cui X, Tu S, You L, Fu J, Chen Z, Hu W, Gong W. PAK5 facilitates the proliferation, invasion and migration in colorectal cancer cells. Cancer Med 2020; 9: 4777-4790 [DOI: 10.1002/cam4.3084]

84. Ausborn NL, Wang T, Wentz SC, Washington MK, Merchant NB, Zhao Z, Shyr Y, Chakravarthy AB, Xia F. 53BP1 expression is a modifier of the prognostic value of lymph node ratio and CA 19-9 in pancreatic adenocarcinoma. BMC Cancer 2013; 13: 155 [PMID: 23530749 DOI: 10.1186/1471-2407-13-155]

85. Ding X, Duan H, Luo H. Identification of Core Gene Expression Signature and Key Pathways in Colorectal Cancer. Front Genet 2020; 11: 45 [PMID: 32153633 DOI: 10.3389/fgene.2020.00045]

86. Wang WF, Xie Y, Zhou ZH, Qin ZH, Wu JC, He JK. PI3KCA hypomethylation plays a key role in activation of the PI3K/AKT pathway in esophageal cancer in Chinese patients. Acta Pharmacol Sin 2013; 34: 1560-1567 [PMID: 24241346 DOI: 10.1038/aps.2013.163]

87. Javel M, Li Y, Tan D, Dong X, Chang P, Kar S, Li D. Biomarkers of TGF-β signaling pathway and prognosis of pancreatic cancer. PLoS One 2014; 9: e85942 [PMID: 24465802 DOI: 10.1371/journal.pone.0085942]

88. Li CW, Chang PY, Chen BS. Investigating the mechanism of hepatocellular carcinoma progression by constructing genetic and epigenetic networks using NGS data identification and big database mining method. Oncotarget 2016; 7: 79453-79473 [PMID: 27821810 DOI: 10.18632/oncotarget.13100]

89. Sang Z, Guo R, Xing R, Zhang L, Li W, Zhao M, Fang J, Hu F, Kang B, Ren Y, Zhuang Y, Liu S, Wang R, Li X, Yu Y, Cheng J, Lu Y. Identification of differentially-expressed genes in intestinal gastric cancer by microarray analysis. Genomics Proteomics Bioinformatics 2014; 12: 276-283 [PMID: 25500430 DOI: 10.1016/j.gpb.2014.09.004]

90. Meng XR, Lu P, Mei JZ, Liu GJ, Fan QX. Expression analysis of miRNA and target mRNAs in esophageal cancer. Braz J Med Biol Res 2014; 47: 811-817 [PMID: 25096614 DOI: 10.1590/1414-431x20143906]

91. Cui X, Xin H, Peng H, Chen Y. Comprehensive bioinformatics analysis of the mRNA profile of PLCE1 knockdown in esophageal squamous cell carcinoma. Mol Med Rep 2017; 16: 5871-5880 [PMID: 28849204 DOI: 10.14740/mmr16432]
Hwang HJ, Nam SK, Park H, Park Y, Koh J, Na HY, Kwak Y, Kim WH, Lee HS. Prediction of TP53 mutations by p53 mutation detection kit in human colorectal cancer cells to 5-fluorouracil by inhibiting the ATM-CHK2-P53 pathway. J Gastroenterol Hepatol 2017; 6: 2370-2375 [DOI: 10.1111/1759-7714.13626].

Zhang Y, Wang J, Yuan M, Ma Z, Bao Y, Hui Z. Multivariate gene expression-based survival predictor model in esophageal squamous cell carcinoma. Oncol Lett 2017; 14: 3689-3696 [PMID: 28927132] [DOI: 10.3892/ol.2017.6616].

Zhang M, Wang J, Yuan M, Ma Z, Bao Y, Hui Z. Multivariate gene expression-based survival predictor model in esophageal adenocarcinoma. Thorac Cancer 2020; 11: 2806-2908 [PMID: 32469055] [DOI: 10.1111/1759-7714.13626].

Cheng Y, Wang K, Geng L, Sun J, Xu W, Liu D, Gong S, Zhi Y. Identification of candidate diagnostic and prognostic biomarkers for pancreatic carcinoma. EihiteMedicine 2019; 40: 382-393 [PMID: 30639415] [DOI: 10.1016/j.jhbm.2019.01.003].

Lánczky A, Györfi B. Web-Based Survival Analysis Tool Tailored for Medical Research (KMerplot): Development and Implementation. J Med Internet Res 2021; 23: e2763 [PMID: 34309654] [DOI: 10.2196/27633].

Hiralal Sankalecha T, Jagdish Gupta S, Rangrao Gaikwad N, Narayanrao Ughade S. Correlation of P53 Expression with Various Clinicopathological Parameters of Gastric Carcinoma and Its Relationship with Survival. J Gastroenterol Hepatol Res 2017; 6: 2370-2375 [DOI: 10.17554/jissn.2224-3992.2017.06.707].

Hwang HJ, Nam SK, Park H, Park Y, Koh J, Na HY, Kwak Y, Kim WH, Lee HS. Prediction of TP53 mutations by p53
immunohistochemistry and their prognostic significance in gastric cancer. *J Pathol Transl Med* 2020; **54**: 378-386 [PMID: 32601264 DOI: 10.4132/jptm.2020.06.01]

145 Ozaki T, Nakagawara A. Role of p53 in Cell Death and Human Cancers. *Cancers (Basel)* 2011; **3**: 994-1013 [PMID: 224212651 DOI: 10.3390/cancers3010994]

146 Petrini I, Lencioni M, Vasile E, Fornaro L, Belluomini L, Pasquini G, Gionocchi L, Caparelo C, Musettini G, Vivaldi C, Caponi S, Ricci S, Proietti A, Fontanini G, Naccarato AG, Nardini V, Santi S, Falcone A. EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas. *Cancer Biomark* 2018; **21**: 731-741 [PMID: 29278835 DOI: 10.3233/CIBM-170865]

147 Zheng CH, Wang JB, Lin MQ, Zhang PY, Liu LC, Lin DX, Lu J, Chen QY, Cao LL, Lin M, Tu RH, Xie JW, Li P, Huang CM. CDK5RAP3 suppresses Wnt/β-catenin signaling by inhibiting AKT phosphorylation in gastric cancer. *J Exp Clin Cancer Res* 2018; **37**: 59 [PMID: 29540196 DOI: 10.1186/s13046-018-0716-4]

148 Di Bartolomeo M, Pietrantonio F, Pellegrinelli A, Martinetti A, Mariani L, Daidone MG, Bajetta E, Pelosi G, de Braud F, Floriani I, Miceli R. Osteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer. *Gastric Cancer* 2016; **19**: 412-420 [PMID: 25862567 DOI: 10.1007/s10120-015-0495-y]

149 Li Z, Han C, Feng J. Relationship of the expression levels of XIAP and p53 genes in hepatocellular carcinoma and the prognosis of patients. *Oncol Lett* 2017; **14**: 4037-4042 [PMID: 28959363 DOI: 10.3892/ol.2017.6681]
